Metabolic Dysfunction

Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with obesity and compensated cirrhosis from metabolic dysfunction-associated steatohepatitis, according to study data.

Gestational diabetes led to an increased risk for asthma exacerbations during pregnancy among a cohort of women with pre-existing asthma, according to results of a retrospective cohort study.

Healio has compiled a list of the most-read nephrology news stories related to diabetes and metabolic dysfunction in 2024.

SAN DIEGO — Once-daily ALG-055009 achieved “significant and robust reductions” in liver fat at 12 weeks and was well-tolerated among noncirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to data.

At 15 years of follow-up, metabolic surgery “was not only safe” but also significantly reduced major adverse liver outcomes and decompensation in patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.

Survodutide was superior to placebo and significantly improved markers of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis, according to data presented at EASL Congress.

WASHINGTON — Researchers have determined that several noninvasive tests could help identify candidates for treatment with Rezdiffra, as well as predict response, in metabolic dysfunction-associated steatohepatitis.

Topline findings from a phase 2 trial showed that survodutide achieved “statistically significant improvement” for metabolic dysfunction-associated steatohepatitis and liver fibrosis in 83% of patients, Boehringer Ingelheim announced.